Here we describe a study to evaluate DNA and RNA sequencing on longitudinal samples taken at diagnosis and at CR, as potential MRD detection tools for post-remission monitoring of CBF-AML. The gene discussed is CEBPZ; the disease is acute myeloid leukemia.